Editor’s Note:
The “Vision for Global Health” is one a series of G7 communiques issued by the meeting. We highlight selected language around public health emergencies and mentions of vaccines and immunization from the Vision for Global Health below. We urge readers to review the full document (see link]

G7 Japan 2016 – Ise-Shima
http://www.japan.go.jp/g7/

.

G7 Ise-Shima Vision for Global Health (PDF: 8 pages)
May 27, 2016
…1-2. Funding mechanism to ensure prompt actions in public health emergencies
1) Recognizing that WHO should play a key leading and coordinating role in the event of an
outbreak, for prompt detection, containment and control of public health emergencies
particularly in the early stage, call on the international community to support the Contingency
Fund for Emergency (CFE) to enable swift initial response by the WHO.
2) Welcome the World Bank’s formal announcement of launching the Pandemic Emergency
Financing Facility (PEF) to support a surge response by governments, multilateral agencies and
NGOs, and invite the international community including G7 members to extend technical
support and financial contributions to this end.
3) Also call upon relevant international organizations to ensure coordination among the PEF and
their related funding mechanisms including the CFE.
4) Urge all countries to improve their prevention and preparedness against outbreaks and
incorporate measures for enhanced national health security over time.

1-3. Coordination arrangement on global public health emergencies
1) Invite the WHO and the Office for the Coordination of Humanitarian Affairs (OCHA) under UN
Secretary General to review, strengthen and formalize coordination arrangement among the
WHO, the UN and other relevant partners in global public health emergencies, while
strengthening existing coordination systems including the Inter Agency Standing Committee
(IASC) Cluster System led by OCHA, as envisioned by on-going processes including the final
report of and UNSG response to UN High-Level Panel, World Humanitarian Summit and WHO
governing body discussions.
2) Invite the WHO and OCHA to update on the progress of these deliberations at the G7 Health
Ministers Meeting in September 2016….

2-1-2. Support for health system strengthening in LICs/LMICs towards UHC
…3) Support LICs/LMICs’s nationally driven and owned efforts toward HSS which might include the following key contributors for the achievement of UHC with better preparedness for and
prevention against emergencies;…
…(iii) improving access to affordable, safe, effective, and quality assured, essential medicines,
vaccines and technologies to prevent, diagnose and treat medical problems…

2-2-1. Women, adolescent and children’s health
…4) Reaffirm the importance of immunization as one of key cost-effective measures to prevent the spread of infectious disease and address emerging pandemics and to this end:
(i) continue global efforts to achieve the targets established in the Global Vaccine Action Plan;
(ii) leverage and use immunization records including information sources such as Maternal and
Child Health(MCH) handbooks which highlight the importance of immunization and give
guidance to families; and
(iii) recognize the tremendous progress achieved towards polio eradication where global
eradication is now within reach, and reaffirm our commitment to achieve polio eradication
targets laid out in the GPEI Endgame Strategic Plan, and recognize the significant
contribution that the polio related assets, resources and infrastructure will have on
strengthening health systems and advancing UHC….

3-4. Improving access to AMR countermeasures
1) Improve access to effective vaccines, diagnostics, antimicrobials, alternate therapeutics.
2) Support Infection Prevention and Control such as good hygiene – in particular but not only in
LICs and LMICs to reduce healthcare – associated infections and health burden of AMR through
appropriate training and technologies, and bilateral or multilateral arrangement.
3) Promote R&D partnerships, and measure the effectiveness of such interventions of effective
vaccines, diagnostics, antimicrobials,

4-1-2. Promote R&D on AMR
1) Promote R&D to combat AMR, such as through “pull” incentives to address specific market
failures and funding for basic and applied research and development of new vaccines,
diagnostics, antimicrobials, alternative therapeutics as well as IPC, other behavioral
interventions, and antimicrobial stewardship programs…

4-2. Accelerate R&D such as testing and manufacturing and distribution of medical products for public health emergencies
1) Acknowledge the importance of ensuring mechanisms to accelerate R&D in public health
emergencies, and welcome the action to prevent epidemics such as WHO Blueprint, discussions
at Global Health Security Initiative and Global Research Collaboration for Infectious Disease
Preparedness (GloPID-R).
2) Explore the feasibility of partnerships such as the Vaccine Innovation for Pandemic
Preparedness Partnership to conduct a coordinated vaccine research and development.
3) Promote scientifically robust clinical trials on emerging infectious diseases for rapid research
responses in cases of outbreak…